Objectives for the STASEY trial focused on the safety of emicizumab in a low-bled population of PwHA and tested the following:

- Safety of long-term treatment with emicizumab
- Tolerability of emicizumab
- Treated bleeds and joint bleeds
- AE rates
- AE-related discontinuations
- Immunogenicity
- Efficacy of emicizumab

Several endpoints were defined to evaluate the efficacy of emicizumab, including:

- Treated bleeds
- Treated joint bleeds
- Treated target joint bleeds
- Number of PwHA with ≥1 event

Primary outcomes were assessed in the safety analysis. Secondary outcomes were evaluated in the efficacy analysis. All results were compared with historical PwHA treatment data from the ISTH registry. The target population was 193 patients, of whom 190 received emicizumab.